Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?
The authors summarized the potential cutaneous side effects of remdesivir, a nucleoside/nucleotide analog treatment and compared them with those observed
Category: Drug delivery
Special Issue “Polymeric Nanoparticles in Drug Delivery”
Special Issue “Polymeric Nanoparticles in Drug Delivery“, in the OPEN ACCESS journal /Applied Sciences/ (ISSN 2076-3417; Impact Factor: 2.474), is
Sevoflurane may affect tau spread in the brain to promote Alzheimer’s disease pathology
According to the press release of Massachusetts General Hospital sevoflurane may induce changes in the brain leading to Alzheimer disease.
Solventless Crosslinking of Chitosan, Xanthan, and Locust Bean Gum Networks Functionalized with β-Cyclodextrin
The incorporation of cyclodextrins into polymeric crosslinked gels of hydrophilic nature can be useful for promoting the sorption of hydrophobic
Antibiotic-in-cyclodextrin-in-liposomes: formulation development and interactions with model bacterial membranes
Gram-negative bacteria possess numerous defenses against antibiotics, due to the intrinsic permeability barrier of their outer membrane, explaining the recalcitrance
Dual-redox sensitive, stabilized supramolecular nanocontainers for potential programmable drug release using a multifunctional cyclodextrin unit
In this work it is reported a one-pot preparation of dual-redox sensitive, stabilized supramolecular nanocontainers for potential programmable drug release
History of cyclodextrin‑based polymers in food and pharmacy: a review
The incorporation of cyclodextrin moieties into larger structures produces five types of new materials: crosslinked networks, functionalized chains, amphiphilic cyclodextrins,
Bridge virtual meeting before the 20th International Cyclodextrin Symposium
As the International Cyclodextrin Symposium (Giardini Naxos, Sicily) has been postponed to 2022 an abridged virtual meeting was organized by
Special issue: “Drug-Cyclodextrin Interactions. A Basis for New Formulations”
A Special issue “Drug-Cyclodextrin Interactions. A Basis for New Formulations” in Molecules (ISSN 1420-3049, http://www.mdpi.com/journal/molecules) will be published. Contributions of either an original research
OCULIS ANNOUNCES AN OVERSUBSCRIBED US$57 MILLION SERIES C FINANCING
New leading international life science investors join current institutional investors with proceeds to: Advance novel, late-stage Investigational ophthalmology drugs OCS-01